EGFR and glioblastoma: ,100 Our results recommend OV-encoded dual-targeting antibodies and more specifically the Db-TriTE-encoding oAd Ad5/3-DMFE for dual-targeting of EGFR and c-MET frequently co-expressed in NSCLC, glioblastoma, and colorectal cancer.